small molecule

NOCDURNA

DESMOPRESSIN ACETATE

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyFerring PharmaceuticalsView the full company profile on CliffBio

Drug detail

Brand nameNOCDURNA
Active ingredientDESMOPRESSIN ACETATE
Strength0.0277MG
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalJune 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
9974826April 2030use U-2326
11963995May 2029use U-2327
11020448May 2029use U-2327

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NOCDURNA patent cliff — loss of exclusivity April 2030 | CliffBio